Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

According to 10 professional analysts, the 12-month price target for Iovance Biotherapeutics stock ranges from a low of $2.00 to a high of $20. The average analyst price target of $11.9 forecasts a 385.71% increase in the stock price over the next year.

Price Target: $11.90 (+385.71%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.00	$11.9	$14	$20
Change	-18.37%	+385.71%	+471.43%	+716.33%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	5	5	4	4	4	4
Buy	2	3	3	3	3	4
Hold	1	1	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	9	10	10	10	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yanan Zhu Wells Fargo	Wells Fargo	Buy Maintains $18 → $14	Buy	Maintains	$18 → $14	+471.43%	Aug 8, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $25 → $20	Strong Buy	Maintains	$25 → $20	+716.33%	Aug 8, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $25	Strong Buy	Maintains	$25	+920.41%	Jul 23, 2025
David Dai UBS	UBS	Strong Buy → Hold Downgrades $17 → $2	Strong Buy → Hold	Downgrades	$17 → $2	-18.37%	May 16, 2025
Andrea Tan Goldman Sachs	Goldman Sachs	Strong Buy Maintains $16 → $8	Strong Buy	Maintains	$16 → $8	+226.53%	May 12, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

306.19M

Increased by 86.62%

from 164.07M

Revenue Next Year

517.87M

Increased by 69.13%

from 306.19M

EPS This Year

-1.16

from -1.28

EPS Next Year

-0.77

from -1.16

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	1.19M	164.07M	306.19M	517.87M	727.28M
Revenue Growth	-	-	-	-	13,698.99%	86.62%	69.13%	40.44%
EPS	-1.88	-2.23	-2.49	-1.89	-1.28	-1.16	-0.77	-0.22
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	14	14	11

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	499.0M	762.4M	1.2B
Avg	306.2M	517.9M	727.3M
Low	245.7M	367.5M	465.5M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	204.1%	149.0%	138.9%
Avg	86.6%	69.1%	40.4%
Low	49.7%	20.0%	-10.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.96	-0.38	0.08
Avg	-1.16	-0.77	-0.22
Low	-1.25	-1.02	-0.53

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.